Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:23:58.737Z.
Consensus retrieved: 2026-10-06T16:40:18.823Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:23:58.737Z.
Quote observation: 2026-10-06T19:20:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7c009322a229257a98230f40e2740bea1b73477c063b99c175921fa35d9c923
Forward PE Ratio (N/A) = Dated Quote Price ($4.75) / Consensus Forward EPS ($-0.09)
FORWARD PE RATIO
N/A
Strata Critical Medical, Inc.
Market Cap
$411.43M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Strata Critical Medical, Inc. (SRTA) | $411.43M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $410.64M | N/A |
| Rezolute, Inc. (RZLT)vs › | $409.72M | N/A |
| Carlsmed, Inc. (CARL)vs › | $407.23M | N/A |
| Neurogene Inc. (NGNE)vs › | $406.51M | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $418.15M | N/A |
| Prothena Corporation plc (PRTA)vs › | $420.92M | 73.09 |
| Myriad Genetics, Inc. (MYGN)vs › | $401.88M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $399.74M | N/A |
Trailing P/E
9.6
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.09 | $-0.09 – $-0.09 | 2 | n/m |
| 2027-12-31 | $0.00 | $-0.14 – $0.08 | 3 | 1426.6x |
| 2028-12-31 | $0.00 | $0.00 – $0.00 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
